Communiqués ALTEOGEN Inc.

Actions

Cours en clôture Korea S.E. 21/09/2026			Varia. 5j.	Varia. 1 janv.
255 000,00 ^KRW	+0,59%		-1,92%	-26,25%

21/09	Le Keytruda QLEX de Merck approuvé au Japon
03/09	Bourse : Snowflake en mode boule de neige, Soitec vise plus haut, Publicis rafle Pepsi

26/03	Alteogen Enters into a License Agreement with Biogen for Development and Commercialization of Hybrozyme-Based Subcutaneous Biologics	AQ
26/08/25	Alteogen's Aflibercept Biosimilar Receives Positive CHMP Opinion	AQ
20/09/24	Alteogen Seeks Approval For Aflibercept Biosimilar In Korea	AQ
02/07/24	Altos Biologics Files Approval of Aflibercept Biosimilar	AQ
03/03/23	Alteogen And Sandoz Enter A Biosimilars Agreement Relating To Subcutaneous Products	AQ
03/01/23	Alteogen enters into an Exclusive License Agreement to Develop and Commercialize Biosimilar Products Enabled by Alteogen's Hybrozyme Technology	AQ